On November 5, 2021, PPMD invited Drs. Tim Cripe and Tim Franson back for another COVID-19 vaccine webinar to provide updates on the new pediatric approval and what it means for the Duchenne community. Our panelists shared important information on vaccine development, impact of COVID-19 on children, vaccine safety in the 5-11 age group, and additional context about third vs. booster doses.

For more information about COVID-19 Vaccines, please visit our COVID-19 Information Center.

Watch: Pediatric COVID-19 Vaccination (ages 5-11) & Duchenne

COVID-19 VACCINES CURRENTLY AVAILABLE

	Pfizer	Moderna	Janssen Biotech/Johnson and Johnson
Vaccine Platform	mRNA encased in lipid nanoparticles (fat bubbles) to keep it from degrading	mRNA encased in lipid nanoparticles (fat bubbles) to keep it from degrading	Recombinant, replication-incompetent human adenovirus type 26 vector
Age of Inclusion	5 years +	18 years +	18 years +
Accessibility	Storage between -94 degrees Fahrenheit (institutional research freezers), stable x5 days after thaw	-4 degrees Fahrenheit (regular freezer), stable x30 days after thaw and at room temperature for 12 hours	36 degrees Fahrenheit to 46 degrees Fahrenheit (regular refrigerator); or 47 degrees Fahrenheit to 77 degrees Fahrenheit (room temperature) for up to 12 hours
Dosing Schedule	2 injections given 21 days apart; 30µg dose given for 12+ and 10µg given for 5-11yrs	2 injections given 28 days apart	Single dose
Efficacy	95% effective	95% effective	85% effective in preventing severe/critical COVID-19 occurring at least 28 days after vaccination, 100% effective in preventing death
Possible Side Effects	Pain at injection site, fatigue, mild fever, headache, muscle pain, joint pain, fever; younger adults have reported more side effects than older adults. *In 5-11 year olds, more redness and swelling at injection site, and less frequent/milder fever.	Pain at injection site, fatigue, mild fever, headache, muscle pain, joint pain, fever; younger adults have reported more side effects than older adults	Pain at the injection site, headache, fatigue, muscle aches and nausea
Additional Doses	Yes, if moderately or severely immunocompromised. Administer at least 28 days after the second dose. Ages 5+.	Yes, if moderately or severely immunocompromised. Administer at least 28 days after the second dose. Ages 18+	Unknown
Booster Doses	Yes, for people 12 years and older, five months after completion of primary series. **Booster shots may be mixed and matched. You can receive the same type you originally received, or receive a different type. CDC recommendations now allow for a mix/match approach to booster administration.	Yes, for people 18 years or older, six months after completion of second (or third) dose, at one-half the original dose. **Booster shots may be mixed and matched. You can receive the same type you originally received, or receive a different type. CDC recommendations now allow for a mix/match approach to booster administration.	Yes, for all people 18+, at least two months after first dose. **Booster shots may be mixed and matched. You can receive the same type you originally received, or receive a different type. CDC recommendations now allow for a mix/match approach to booster administration.
Approval	Full FDA approval for 18+; Emergency Use Authorization for 5-11 and 12-17	Emergency Use Authorization	Emergency Use Authorization

* Table reflects COVID-19 vaccines that have received emergency use authorization from the US Food and Drug Administration (FDA) as of November 2, 2021.